Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128835

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128835

NA Anthrax Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 255 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

North America anthrax treatment market is projected to register a CAGR of 4.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the anthrax treatment market are:

Rising prevalence of anthrax infections

Increasing research funding and the development of novel therapies for anthrax treatment

Market Players:

The key market players for North America anthrax treatment market are listed below:

Alembic Pharmaceuticals

Integrated Bio Therapeutics Inc.

Sun Pharmaceutical Industries Ltd.

Zydus Group

Bayer AG

Pfizer Inc.

EMERGENT

Sanofi

Elusys Therapeutics

Lupin

Soligenix

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

INDOCO REMEDIES LTD.

Paratek Pharmaceuticals, Inc.

BlueWillow Biologics.

Altimmune

TABLE OF CONTENTS

1 INTRODUCTION 74

  • 1.1 OBJECTIVES OF THE STUDY 74
  • 1.2 MARKET DEFINITION 74
  • 1.3 OVERVIEW OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET 74
  • 1.4 LIMITATIONS 76
  • 1.5 MARKETS COVERED 76

2 MARKET SEGMENTATION 79

  • 2.1 MARKETS COVERED 79
  • 2.2 GEOGRAPHICAL SCOPE 80
  • 2.3 YEARS CONSIDERED FOR THE STUDY 81
  • 2.4 CURRENCY AND PRICING 81
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
  • 2.6 MULTIVARIATE MODELLING 85
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 85
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
  • 2.9 DBMR MARKET POSITION GRID 87
  • 2.10 MARKET APPLICATION COVERAGE GRID 88
  • 2.11 VENDOR SHARE ANALYSIS 89
  • 2.12 SECONDARY SOURCES 90
  • 2.13 ASSUMPTIONS 90

3 EXECUTIVE SUMMARY 91

4 PREMIUM INSIGHTS 95

  • 4.1 PESTEL ANALYSIS 96
  • 4.2 PORTER'S FIVE FORCES 97
  • 4.3 DEMOGRAPHIC TRENDS- 98
  • 4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
    • 4.4.1 INCIDENCE 100
    • 4.4.2 DEVELOPED COUNTRIES- 100
    • 4.4.3 DEVELOPING COUNTRIES- 100
  • 4.5 PATIENT ENROLMENT STRATEGIES- 102
  • 4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
  • 4.7 CURRENT STATE OF ANTHRAX VACCINES 108
  • 4.8 NORTH AMERICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
  • 4.9 NORTH AMERICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113

5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR'S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY'S PIPELINE FOR ANTHRAX TREATMENT. 117

6 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGULATIONS 119

7 MARKET OVERVIEW 123

  • 7.1 DRIVERS 125
    • 7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
    • 7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
    • 7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
    • 7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
  • 7.2 RESTRAINTS 127
    • 7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
    • 7.2.2 FALSE DATA INTERPRETATION 128
  • 7.3 OPPORTUNITIES 128
    • 7.3.1 RISING PRODUCT LAUNCHES 128
    • 7.3.2 RISING GOVERNMENT INITIATIVES 129
    • 7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
  • 7.4 CHALLENGES 130
    • 7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
    • 7.4.2 LACK OF SKILLED PROFESSIONALS 130

8 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE 132

  • 8.1 OVERVIEW 133
  • 8.2 CUTANEOUS ANTHRAX 136
    • 8.2.1 ANTIBIOTICS 137
      • 8.2.1.1 BY DRUGS 137
        • 8.2.1.1.1 CIPROFLOXACIN 138
        • 8.2.1.1.2 LEVOFLOXACIN 138
        • 8.2.1.1.3 DOXYCYCLINE 138
        • 8.2.1.1.4 AMPICILLIN 138
        • 8.2.1.1.5 OTHERS 138
      • 8.2.1.2 BY PRODUCT TYPES 138
        • 8.2.1.2.1 GENERICS 138
        • 8.2.1.2.2 BRANDED 138
        • 8.2.1.2.2.1 CIPRO 139
        • 8.2.1.2.2.2 LEVO 139
        • 8.2.1.2.2.3 DOXY 139
        • 8.2.1.2.2.4 AMPICI 139
        • 8.2.1.2.2.5 OTHERS 139
    • 8.2.2 ANTITOXINS 140
      • 8.2.2.1 RAXIBACUMAB 140
      • 8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
      • 8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
      • 8.2.2.4 OTHERS 140
    • 8.2.3 VACCINES 141
      • 8.2.3.1 RAXIBACUMAB 141
    • 8.2.4 SURGERY 141
  • 8.3 PULMONARY ANTHRAX 141
    • 8.3.1 ANTIBIOTICS 142
      • 8.3.1.1 BY DRUGS 143
        • 8.3.1.1.1 CIPROFLOXACIN 143
        • 8.3.1.1.2 LEVOFLOXACIN 143
        • 8.3.1.1.3 DOXYCYCLINE 143
        • 8.3.1.1.4 AMPICILLIN 143
        • 8.3.1.1.5 OTHERS 143
      • 8.3.1.2 BY PRODUCT TYPES 144
        • 8.3.1.2.1 GENERICS 144
        • 8.3.1.2.2 BRANDED 144
        • 8.3.1.2.2.1 CIPRO 144
        • 8.3.1.2.2.2 LEVO 145
        • 8.3.1.2.2.3 DOXY 145
        • 8.3.1.2.2.4 AMPICI 145
        • 8.3.1.2.2.5 OTHERS 145
    • 8.3.2 ANTITOXINS 145
      • 8.3.2.1 RAXIBACUMAB 145
      • 8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
      • 8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
      • 8.3.2.4 OTHERS 146
    • 8.3.3 VACCINES 146
      • 8.3.3.1 RAXIBACUMAB 146
      • 8.3.3.2 SURGERY 146
  • 8.4 INTESTINAL ANTHRAX 146
    • 8.4.1 ANTIBIOTICS 148
      • 8.4.1.1 BY DRUGS 148
        • 8.4.1.1.1 CIPROFLOXACIN 148
        • 8.4.1.1.2 LEVOFLOXACIN 148
        • 8.4.1.1.3 DOXYCYCLINE 148
        • 8.4.1.1.4 AMPICILLIN 149
        • 8.4.1.1.5 OTHERS 149
      • 8.4.1.2 BY PRODUCT TYPES 149
        • 8.4.1.2.1 GENERICS 149
        • 8.4.1.2.2 BRANDED 149
        • 8.4.1.2.2.1 CIPRO 150
        • 8.4.1.2.2.2 LEVO 150
        • 8.4.1.2.2.3 DOXY 150
        • 8.4.1.2.2.4 AMPICI 150
        • 8.4.1.2.2.5 OTHERS 150
    • 8.4.2 ANTITOXINS 151
      • 8.4.2.1 RAXIBACUMAB 151
      • 8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
      • 8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
      • 8.4.2.4 OTHERS 151
    • 8.4.3 VACCINES 152
      • 8.4.3.1 RAXIBACUMAB 152
      • 8.4.3.2 SURGERY 152

9 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153

  • 9.1 OVERVIEW 154
  • 9.2 PARENTERAL 157
  • 9.3 ORAL 157
  • 9.4 OTHERS 158

10 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER 159

  • 10.1 OVERVIEW 160
  • 10.2 GOVERNMENT ORGANIZATION 163
  • 10.3 HOSPITALS 163
  • 10.4 ACADEMIC AND RESEARCH 164
  • 10.5 OTHERS 166

11 NORTH AMERICA VIRTUAL REALITY MARKET, BY GEOGRAPHY 167

  • 11.1 NORTH AMERICA 168
    • 11.1.1 U.S. 185
    • 11.1.2 CANADA 195
    • 11.1.3 MEXICO 205

12 NORTH AMERICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 215

  • 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 215

13 SWOT ANALYSIS 216

14 COMPANY PROFILE 217

  • 14.1 BAYER AG 217
    • 14.1.1 COMPANY SNAPSHOT 217
    • 14.1.2 REVENUE ANALYSIS 217
    • 14.1.3 COMPANY SHARE ANALYSIS 218
    • 14.1.4 PRODUCT PORTFOLIO 218
    • 14.1.5 RECENT DEVELOPMENTS 218
  • 14.2 PFIZER INC. 219
    • 14.2.1 COMPANY SNAPSHOT 219
    • 14.2.2 REVENUE ANALYSIS 219
    • 14.2.3 COMPANY SHARE ANALYSIS 220
    • 14.2.4 PRODUCT PORTFOLIO 220
    • 14.2.5 RECENT DEVELOPMENTS 220
  • 14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 221
    • 14.3.1 COMPANY SNAPSHOT 221
    • 14.3.2 REVENUE ANALYSIS 221
    • 14.3.3 COMPANY SHARE ANALYSIS 222
    • 14.3.4 PRODUCT PORTFOLIO 222
    • 14.3.5 RECENT DEVELOPMENT 222
  • 14.4 SANOFI 223
    • 14.4.1 COMPANY SNAPSHOT 223
    • 14.4.2 REVENUE ANALYSIS 223
    • 14.4.3 COMPANY SHARE ANALYSIS 224
    • 14.4.4 PRODUCT PORTFOLIO 224
    • 14.4.5 RECENT DEVELOPMENTS 224
  • 14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 225
    • 14.5.1 COMPANY SNAPSHOT 225
    • 14.5.2 REVENUE ANALYSIS 225
    • 14.5.3 PRODUCT PORTFOLIO 226
    • 14.5.4 RECENT DEVELOPMENT 226
  • 14.6 ALEMBIC PHARMACEUTICALS LIMITED 227
    • 14.6.1 COMPANY SNAPSHOT 227
    • 14.6.2 PRODUCT PORTFOLIO 227
    • 14.6.3 RECENT DEVELOPMENTS 227
  • 14.7 ALTIMMUNE 228
    • 14.7.1 COMPANY SNAPSHOT 228
    • 14.7.2 REVENUE ANALYSIS 228
    • 14.7.3 PRODUCT PORTFOLIO 229
    • 14.7.4 RECENT DEVELOPMENTS 229
  • 14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 230
    • 14.8.1 COMPANY SNAPSHOT 230
    • 14.8.2 PRODUCT PORTFOLIO 230
    • 14.8.3 RECENT DEVELOPMENTS 230
  • 14.9 BLUEWILLOW BIOLOGICS. 231
    • 14.9.1 COMPANY SNAPSHOT 231
    • 14.9.2 PRODUCT PORTFOLIO 231
    • 14.9.3 RECENT DEVELOPMENTS 231
  • 14.10 DEINOVE 232
    • 14.10.1 COMPANY SNAPSHOT 232
    • 14.10.2 REVENUE ANALYSIS 232
    • 14.10.3 PRODUCT PORTFOLIO 233
    • 14.10.4 RECENT DEVELOPMENTS 233
  • 14.11 EMERGENT 234
    • 14.11.1 COMPANY SNAPSHOT 234
    • 14.11.2 REVENUE ANALYSIS 234
    • 14.11.3 PRODUCT PORTFOLIO 235
    • 14.11.4 RECENT DEVELOPMENTS 235
  • 14.12 ELUSYS THERAPEUTICS INC. 236
    • 14.12.1 COMPANY SNAPSHOT 236
    • 14.12.2 PRODUCT PORTFOLIO 236
    • 14.12.3 RECENT DEVELOPMENTS 236
  • 14.13 GC BIOPHARMA CORP. 237
    • 14.13.1 COMPANY SNAPSHOT 237
    • 14.13.2 REVENUE ANALYSIS 237
    • 14.13.3 PRODUCT PORTFOLIO 238
    • 14.13.4 RECENT DEVELOPMENTS 238
  • 14.14 INDOCO REMEDIES LTD. 239
    • 14.14.1 COMPANY SNAPSHOT 239
    • 14.14.2 REVENUE ANALYSIS 239
    • 14.14.3 PRODUCT PORTFOLIO 240
    • 14.14.4 RECENT DEVELOPMENTS 240
  • 14.15 INTEGRATED BIOTHERAPEUTICS, INC. 241
    • 14.15.1 COMPANY SNAPSHOT 241
    • 14.15.2 PRODUCT PORTFOLIO 241
    • 14.15.3 RECENT DEVELOPMENTS 241
  • 14.16 LUPIN. 242
    • 14.16.1 COMPANY SNAPSHOT 242
    • 14.16.2 REVENUE ANALYSIS 242
    • 14.16.3 PRODUCT PORTFOLIO 243
    • 14.16.4 RECENT DEVELOPMENTS 243
  • 14.17 PARATEK PHARMACEUTICALS, INC. 244
    • 14.17.1 COMPANY SNAPSHOT 244
    • 14.17.2 REVENUE ANALYSIS 244
    • 14.17.3 PRODUCT PORTFOLIO 245
    • 14.17.4 RECENT DEVELOPMENTS 245
  • 14.18 PORTON BIOPHARMA 246
    • 14.18.1 COMPANY SNAPSHOT 246
    • 14.18.2 PRODUCT PORTFOLIO 246
    • 14.18.3 RECENT DEVELOPMENTS 246
  • 14.19 SOLIGENIX 247
    • 14.19.1 COMPANY SNAPSHOT 247
    • 14.19.2 REVENUE ANALYSIS 247
    • 14.19.3 PRODUCT PORTFOLIO 248
    • 14.19.4 RECENT DEVELOPMENTS 248
  • 14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 249
    • 14.20.1 COMPANY SNAPSHOT 249
    • 14.20.2 REVENUE ANALYSIS 249
    • 14.20.3 PRODUCT PORTFOLIO 250
    • 14.20.4 RECENT DEVELOPMENTS 250
  • 14.21 ZYDUS GROUP 251
    • 14.21.1 COMPANY SNAPSHOT 251
    • 14.21.2 REVENUE ANALYSIS 251
    • 14.21.3 PRODUCT PORTFOLIO 252
    • 14.21.4 RECENT DEVELOPMENTS 252

15 QUESTIONNAIRE 253

RELATED REPORTS 255

LIST OF TABLES

  • TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020- 47
  • TABLE 2 VACCINES IN DEVELOPMENT 56
  • TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018- 63
  • TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION- 64
  • TABLE 5 RECENT M&A IN ANTHRAX MARKET- 65
  • TABLE 6 ANTIBIOTICS MEDICINES 68
  • TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED 70
  • TABLE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION) 83
  • TABLE 9 NORTH AMERICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 10 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 11 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 12 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 13 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 86
  • TABLE 14 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 87
  • TABLE 15 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 88
  • TABLE 16 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 89
  • TABLE 17 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 18 NORTH AMERICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 90
  • TABLE 19 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 90
  • TABLE 20 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 91
  • TABLE 21 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 92
  • TABLE 22 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 92
  • TABLE 23 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 93
  • TABLE 24 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 94
  • TABLE 25 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 26 NORTH AMERICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 95
  • TABLE 27 NORTH AMERICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 28 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 29 NORTH AMERICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 97
  • TABLE 30 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 98
  • TABLE 31 NORTH AMERICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 99
  • TABLE 32 NORTH AMERICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 100
  • TABLE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 104
  • TABLE 34 NORTH AMERICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 105
  • TABLE 35 NORTH AMERICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 36 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 110
  • TABLE 38 NORTH AMERICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 111
  • TABLE 39 NORTH AMERICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 112
  • TABLE 40 NORTH AMERICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 41 NORTH AMERICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 114
  • TABLE 42 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 120
  • TABLE 43 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 120
  • TABLE 44 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 120
  • TABLE 45 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 120
  • TABLE 46 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 121
  • TABLE 47 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 121
  • TABLE 48 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 121
  • TABLE 49 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 122
  • TABLE 50 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 122
  • TABLE 51 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 122
  • TABLE 52 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 122
  • TABLE 53 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 123
  • TABLE 54 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 123
  • TABLE 55 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 123
  • TABLE 56 NORTH AMERICA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 124
  • TABLE 57 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 124
  • TABLE 58 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 124
  • TABLE 59 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 124
  • TABLE 60 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 124
  • TABLE 61 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 125
  • TABLE 62 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 125
  • TABLE 63 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 125
  • TABLE 64 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 125
  • TABLE 65 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 126
  • TABLE 66 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 126
  • TABLE 67 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 126
  • TABLE 68 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 127
  • TABLE 69 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 127
  • TABLE 70 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 127
  • TABLE 71 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 128
  • TABLE 72 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 128
  • TABLE 73 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 128
  • TABLE 74 NORTH AMERICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 128
  • TABLE 75 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 128
  • TABLE 76 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 129
  • TABLE 77 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 129
  • TABLE 78 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 129
  • TABLE 79 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 129
  • TABLE 80 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 130
  • TABLE 81 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 130
  • TABLE 82 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 130
  • TABLE 83 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 131
  • TABLE 84 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 131
  • TABLE 85 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 131
  • TABLE 86 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 132
  • TABLE 87 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 132
  • TABLE 88 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 132
  • TABLE 89 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 132
  • TABLE 90 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 132
  • TABLE 91 U.S. ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 133
  • TABLE 92 U.S. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 133
  • TABLE 93 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 133
  • TABLE 94 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 133
  • TABLE 95 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 134
  • TABLE 96 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 134
  • TABLE 97 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 134
  • TABLE 98 U.S. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 135
  • TABLE 99 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 135
  • TABLE 100 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 135
  • TABLE 101 U.S. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 135
  • TABLE 102 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 135
  • TABLE 103 U.S. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 136
  • TABLE 104 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 137
  • TABLE 105 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 137
  • TABLE 106 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 137
  • TABLE 107 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 137
  • TABLE 108 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 138
  • TABLE 109 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 138
  • TABLE 110 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 138
  • TABLE 111 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 138
  • TABLE 112 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 139
  • TABLE 113 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 139
  • TABLE 114 U.S. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 139
  • TABLE 115 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 139
  • TABLE 116 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 139
  • TABLE 117 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 140
  • TABLE 118 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 140
  • TABLE 119 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 140
  • TABLE 120 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 141
  • TABLE 121 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 141
  • TABLE 122 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 142
  • TABLE 123 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 142
  • TABLE 124 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 142
  • TABLE 125 U.S. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 142
  • TABLE 126 U.S. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 142
  • TABLE 127 CANADA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 143
  • TABLE 128 CANADA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 143
  • TABLE 129 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 143
  • TABLE 130 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 143
  • TABLE 131 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 144
  • TABLE 132 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 144
  • TABLE 133 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 144
  • TABLE 134 CANADA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 145
  • TABLE 135 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 145
  • TABLE 136 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 145
  • TABLE 137 CANADA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 145
  • TABLE 138 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 146
  • TABLE 139 CANADA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 146
  • TABLE 140 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 146
  • TABLE 141 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 146
  • TABLE 142 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 146
  • TABLE 143 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 147
  • TABLE 144 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 147
  • TABLE 145 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 147
  • TABLE 146 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 148
  • TABLE 147 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 148
  • TABLE 148 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 148
  • TABLE 149 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 149
  • TABLE 150 CANADA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 149
  • TABLE 151 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 149
  • TABLE 152 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 149
  • TABLE 153 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 150
  • TABLE 154 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 150
  • TABLE 155 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 150
  • TABLE 156 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 151
  • TABLE 157 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 151
  • TABLE 158 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 151
  • TABLE 159 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 151
  • TABLE 160 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 151
  • TABLE 161 CANADA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 152
  • TABLE 162 CANADA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 152
  • TABLE 163 MEXICO ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 153
  • TABLE 164 MEXICO CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 153
  • TABLE 165 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 153
  • TABLE 166 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 153
  • TABLE 167 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 154
  • TABLE 168 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 154
  • TABLE 169 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 154
  • TABLE 170 MEXICO BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 154
  • TABLE 171 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 155
  • TABLE 172 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 155
  • TABLE 173 MEXICO VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 155
  • TABLE 174 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 155
  • TABLE 175 MEXICO PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 155
  • TABLE 176 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 156
  • TABLE 177 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 156
  • TABLE 178 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 156
  • TABLE 179 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 157
  • TABLE 180 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 157
  • TABLE 181 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 157
  • TABLE 182 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 158
  • TABLE 183 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 158
  • TABLE 184 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 158
  • TABLE 185 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 159
  • TABLE 186 MEXICO INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 159
  • TABLE 187 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 159
  • TABLE 188 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 159
  • TABLE 189 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 160
  • TABLE 190 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 160
  • TABLE 191 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 160
  • TABLE 192 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 160
  • TABLE 193 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 161
  • TABLE 194 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 161
  • TABLE 195 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 161
  • TABLE 196 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 161
  • TABLE 197 MEXICO ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 161
  • TABLE 198 MEXICO ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 162

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION 26
  • FIGURE 2 NORTH AMERICA ANTHRAX TREATMENT MARKET: DATA TRIANGULATION 29
  • FIGURE 3 NORTH AMERICA ANTHRAX TREATMENT MARKET: DROC ANALYSIS 30
  • FIGURE 4 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 31
  • FIGURE 5 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 31
  • FIGURE 6 NORTH AMERICA ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 33
  • FIGURE 7 NORTH AMERICA ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID 34
  • FIGURE 8 NORTH AMERICA ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID 35
  • FIGURE 9 NORTH AMERICA ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS 36
  • FIGURE 10 NORTH AMERICA ANTHRAX TREATMENT MARKET: SEGMENTATION 40
  • FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 41
  • FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD 42
  • FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET IN 2022 & 2029 42
  • FIGURE 14 NORTH AMERICA DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS- 45
  • FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX- 53
  • FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE- 54
  • FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532). 57
  • FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA). 58
  • FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR- 61
  • FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA ANTHRAX TREATMENT MARKET 71
  • FIGURE 21 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2021 80
  • FIGURE 22 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION) 81
  • FIGURE 23 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029) 81
  • FIGURE 24 NORTH AMERICA ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE 82
  • FIGURE 25 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021 101
  • FIGURE 26 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 102
  • FIGURE 27 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 102
  • FIGURE 28 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 103
  • FIGURE 29 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2021 107
  • FIGURE 30 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION) 108
  • FIGURE 31 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029) 108
  • FIGURE 32 NORTH AMERICA ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE 109
  • FIGURE 33 NORTH AMERICA ANTHRAX TREATMENT MARKET: SNAPSHOT (2021) 116
  • FIGURE 34 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021) 117
  • FIGURE 35 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029) 117
  • FIGURE 36 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029) 118
  • FIGURE 37 NORTH AMERICA ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029) 118
  • FIGURE 38 NORTH AMERICA ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%) 162
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!